Quinn vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-10-09
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionQuinnIsomorphic Labs
PricingContact for pricing (custom per engagement)Contact for pricing (deep pharma partnerships only)
Target UserR&D teams at biotechs, pharma, academic spinoutsLarge pharma companies with partnership models
Core TechnologyAI synthesis of public/private data for drug development decisionsPredictive and generative AI models using AlphaFold
DeploymentAI-as-a-service with 30-min scoping call, output in 2–5 daysDeep collaborative partnerships on large-scale programs
Key IntegrationsNo integrations listedNo integrations listed
Latest News2026-06-29: Hacker News post about 'Quinn the Eskimo' wisdom repo2026-05-12: Series B investment round; 2026-01-20: J&J collaboration

Choose Quinn if you need actionable, defendable R&D decisions in days without committing to a long-term partnership. Choose Isomorphic Labs if you are a large pharma aiming to embed deep AI capabilities in your discovery pipeline via a strategic collaboration. They serve completely different needs—Quinn for agile decisions, Isomorphic for scale partnerships.

Quinn
Quinn

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

Visit Website
Isomorphic Labs
Isomorphic Labs

Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
—
—
Popularity
5 views
7.5k views
Skill Level
Advanced
Advanced
API Available
Platforms
—
—
Categories
🧬 Drug Discovery & Life Sciences
🧬 Drug Discovery & Life Sciences
Features
Target assessment and prioritization covering human biology, mechanism, druggability, safety, and competitive picture
Computational molecule, binder, and protein design assessed against your criteria
Structure-based chemistry and lead optimization support
Omics and screening data analysis with interpretable findings and reproducible code
Biomarker and patient population selection with a plan to resolve remaining uncertainty
Exposure–response modeling and PK/PD analysis
Trial design with population, endpoint, comparator, and dose recommendations
Statistical design and simulations where the evidence supports them
Mechanistic safety assessment with therapeutic window and class evidence review
CMC assessment covering process, formulation, analytical, and regulatory gaps
Regulatory strategy and precedent assessment, plus drafted scientific sections
Portfolio prioritization, valuation scenarios, and resource allocation analysis
Scientific and commercial due diligence for licensing, acquisition, and partnership
Commercial positioning: pricing, market access, launch sequencing, lifecycle strategy
Executive summary, detailed assessment, and supporting work delivered in 3–5 days
Drug Design Engine spanning generative molecule design through lead optimization
Predictive AI models that anticipate how candidate drugs will perform
Generative models for designing novel molecules
Builds on and beyond the Nobel-winning AlphaFold system
End-to-end research collaborations from target identification to lead optimization
Digital biology approach aimed at discovery at digital speed
Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
Joined the Virtual Biology Initiative to build foundational data for AI disease models
Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
Bioresilience framework for biological threats and health emergencies
Series B investment round announced May 2026 to scale the Drug Design Engine
Follows a $600M external raise in March 2025
President Max Jaderberg appointed November 2025 to integrate AI and science
Interdisciplinary team of drug discovery experts and ML specialists
Founded by Demis Hassabis, who serves as CEO

What real users say: Quinn vs Isomorphic Labs

Not marketing copy and not our opinion — a structured sweep of public discussion (reviews, forums, communities and video comments), showing what people praise and what they complain about for each tool.

Quinn

65 mentions across 3 sources · 22% positive — critical (averaged across 3 sources)

Hacker News, App Store, Lemmy

What users praise

  • • Targeted at high-stakes pharma decisions with structured outputs.
  • • Covers full R&D lifecycle from discovery to commercialization.
  • • Produces reproducible code and validation protocols.
  • • SOC 2 Type II certified for data security.

What frustrates them

  • • No independent user reviews available to verify claims.
  • • Pricing is opaque with no free tier or trial.
  • • Name collision with popular audio app may cause confusion.
  • • 30-minute scoping call adds initial friction.

Researched Jul 3, 2026

Isomorphic Labs

No verifiable community signal. We scanned public discussion on Oct 7, 2026 and found posts matching the name “Isomorphic Labs”, but could not establish that they are about this product rather than something else sharing its name. Rather than publish a score built on the wrong subject, we publish none.

Who should pick which

  • Solo founder
    Pick: Quinn

    Quinn provides fast, defendable decisions for drug development questions without requiring a partnership or large budget, ideal for early-stage biotech.

  • Large pharma R&D team
    Pick: Isomorphic Labs

    Isomorphic Labs offers deep integration into large-scale drug discovery pipelines via strategic collaborations, leveraging AlphaFold and AI models.

  • Translational scientist
    Pick: Quinn

    Quinn's target validation, biomarker selection, and MoA elucidation outputs are tailored for translational decision-making in a matter of days.

  • Biotech governance committee
    Pick: Quinn

    Quinn's scored shortlists and validation protocols support governance discussions for indication prioritization and program decisions.

  • Late-stage pipeline lead optimizer
    Pick: Isomorphic Labs

    Isomorphic's Drug Design Engine with predictive/generative models accelerates lead optimization at scale, suitable for large programs.

Frequently Asked Questions

Quinn vs Isomorphic Labs: which should you choose?

Choose Quinn if you need actionable, defendable R&D decisions in days without committing to a long-term partnership. Choose Isomorphic Labs if you are a large pharma aiming to embed deep AI capabilities in your discovery pipeline via a strategic collaboration. They serve completely different needs—Quinn for agile decisions, Isomorphic for scale partnerships.

What types of questions does Quinn answer?

Quinn answers drug development questions such as indication prioritization, target validation, biomarker selection, trial design, competitive intelligence, regulatory gaps, and MoA elucidation.

Can I use Isomorphic Labs as a small startup?

Isomorphic Labs partners exclusively with large pharma companies (Novartis, J&J) on large-scale programs; it is not designed for startups or individual researchers.

How long does Quinn take to deliver an analysis?

Quinn delivers structured outputs in 2–5 days after a 30-minute scoping call.

Does Isomorphic Labs provide a software API?

No, Isomorphic Labs operates through collaborative partnerships, not as a standalone API or software product.

Is Quinn HIPAA compliant?

Yes, Quinn is HIPAA compliant and SOC 2 Type II certified.

What is the latest funding news for Isomorphic Labs?

Isomorphic Labs raised a $600M external investment round in 2025 and closed a Series B in May 2026 (amount undisclosed).

Does Quinn train on customer data?

No, Quinn states it never trains on customer data.

Are there any free tiers for either tool?

No, both require contacting sales for pricing; no free tiers are available.

More Quinn or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026